Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States—October 25, 2020–February 26, 2022-Reference-Cited by-同舟云学术

Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States—October 25, 2020–February 26, 2022

Published:2023-02 Issue: Volume:18 Page:100403
ISSN:2667-193X
Container-title:The Lancet Regional Health - Americas
language:en
Short-container-title:The Lancet Regional Health - Americas

Author:

Wiegand Ryan E.^ORCID,Deng Yangyang^ORCID,Deng Xiaoyi,Lee Adam,Meyer William A.,Letovsky Stanley,Charles Myrna D.,Gundlapalli Adi V.,MacNeil Adam,Hall Aron J.,Thornburg Natalie J.,Jones Jefferson,Iachan Ronaldo,Clarke Kristie E.N.

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Internal Medicine,Health Policy

Reference50 articles.

1. First case of 2019 novel coronavirus in the United States;Holshue;N Engl J Med,2020

2. Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data;McNamara;Lancet,2021

3. Confronting the delta variant of SARS-CoV-2, summer 2021;del Rio;JAMA,2021

4. SARS-CoV-2 B.1.1.529 (omicron) variant - United States, December 1-8, 2021;MMWR Morb Mortal Wkly Rep,2021

5. Spatial and temporal trends in social vulnerability and COVID-19 incidence and death rates in the United States;Neelon;PLoS One,2021

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. School mask policies and SARS-CoV-2 seroprevalence among school-age children—United States, September to December 2021;Microbiology Spectrum;2024-08-28

2. Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection;2024-08-05

3. Infectious disease surveillance needs for the United States: lessons from Covid-19;Frontiers in Public Health;2024-07-15

4. Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021–June 2022;Influenza and Other Respiratory Viruses;2024-07

5. Differences in SARS-CoV-2 antibodies depending on age, blood group, and sex in a Swedish blood donor cohort;Scandinavian Journal of Clinical and Laboratory Investigation;2024-06-21